AbbVie
ABBV
2,001 hedge funds and large institutions have $109B invested in AbbVie in 2017 Q4 according to their latest regulatory filings, with 275 funds opening new positions, 579 increasing their positions, 911 reducing their positions, and 51 closing their positions.
439% more first-time investments, than exits
New positions opened: 275 | Existing positions closed: 51
11% more funds holding
Funds holding: 1,798 → 2,001 (+203)
9% more capital invested
Capital invested by funds: $99.5B → $109B (+$9.24B)
3% more funds holding in top 10
Funds holding in top 10: 160 → 164 (+4)
0.2% more ownership
Funds ownership: 70.28% → 70.47% (+0.2%)
34% less call options, than puts
Call options by funds: $1.04B | Put options by funds: $1.56B
36% less repeat investments, than reductions
Existing positions increased: 579 | Existing positions reduced: 911
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$610M |
| 2 |
Jennison Associates
New York
|
+$493M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$377M |
| 4 |
Goldman Sachs
New York
|
+$314M |
| 5 |
BlackRock
New York
|
+$256M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$418M |
| 2 |
GCM
Glenview Capital Management
New York
|
-$375M |
| 3 |
WIM
Woodford Investment Management
London,
United Kingdom
|
-$344M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$274M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$268M |
ABBV Hedge Fund Activity: Q4 2017 in Review
2,001 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q4 2017, worth a combined $109B — up 9.3% from $99.5B a quarter earlier.
Buyers outnumbered sellers: 275 funds opened new ABBV positions and 51 closed out — a net gain of 224 holders — while 579 added to existing stakes and 911 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $610M. The largest seller was Federated Hermes, cutting an estimated $418M.
- 2,001 institutional investors held AbbVie (ABBV) as of Q4 2017, up from 1,798 in Q3 2017.
- Funds reported $109B of AbbVie stock for Q4 2017, up 9.3% quarter-over-quarter.
- 275 funds opened new AbbVie positions in Q4 2017 and 51 closed out, a net change of +224 holders.
- The largest AbbVie buyer in Q4 2017 was Fidelity Investments, an estimated $610M added.
- The largest AbbVie seller in Q4 2017 was Federated Hermes, an estimated $418M sold.
Based on aggregated 13F filings for Q4 2017.